Core Viewpoint - The stock of Aidi Kang Holdings (09860) experienced a significant increase, closing up 9.27% at 6.6 HKD, with a trading volume of 41.53 million HKD, indicating positive market sentiment towards the company and the industry as a whole [1] Group 1: Industry Insights - Goldman Sachs' latest report suggests that the Chinese diagnostic industry, including Independent Clinical Laboratories (ICL) and In Vitro Diagnostic (IVD) companies, is expected to show signs of recovery starting from Q3 2025 [1] - In the ICL sector, both Kingmed and Dian Diagnostics reported improvements in operating cash flow, with a sequential increase in revenue and an expansion in profit margins, despite not meeting revenue targets [1] - CITIC Securities noted that the revenue decline in the ICL sector has narrowed in Q3 2025, although profitability remains impacted by impairments [1] Group 2: Company Performance - Aidi Kang reported a gross profit of 450 million and a net profit of 43 million, making it the most profitable among the top three ICL companies [1] - Dian Diagnostics achieved a turnaround, reporting a net profit of 10.27 million during the same period, while Kingmed remains in a loss position [1]
港股异动 | 艾迪康控股(09860)收涨逾9% 高盛称诊断行业开始显现复苏迹象 公司业绩表现好于ICL同行